McKesson Corporation NYQ · MCK
Price alert —
Sign in to get a one-time email the moment MCK crosses your price. Free accounts included.
Sign in / create a free accountMcKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.
MCK last traded at $831.46, down 1.2% on the day; that's in the middle part of its 52-week range ($723.68–$999.00). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.
Earnings reports are the biggest scheduled catalysts to keep an eye on, and after a strong run, watch whether the price can hold its gains on quieter days.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
KC1 upper, +1.48 ATR from EMA21 — no notable pattern
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · KC1 upper stretch — light pop
- · RSI hook from overbought (62)
- · Aligned with weak downtrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
On the latest daily bar, momentum sits mid-range (RSI 62), the trend is quiet (ADX 20), and trading is light at 0.4× normal volume. On the business side, revenue is growing 6% year over year and the business keeps about 1 cents of every sales dollar as free cash.
Latest-bar indicator readings behind the grade — display-only, they don't move the letter.
Company fundamentals for context — display-only, they don't move the grade.
Our cash-flow model pegs fair value near $858.55 (fair range $664–$10337); today's price leaves a +7% cushion below that estimate. The model's verdict is “Fair” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Positive retained earnings
- ⚠ Debt exceeds cash
- ⚠ Quick ratio 0.42 (fragile)
Price implies ~5% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
MCK is a $95.1 billion company, priced at 22× last year's earnings, and it moves more calmly than the market (beta 0.3).
Options idea
See more →Earnings
See more →- Last reported
- 2026-05-07
- EPS (act / est)
- 11.69 / 11.57
- Surprise
- +1.1%
- Next report
- 2026-08-05
About
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-…